Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biopharmaceutical company advancing novel therapies for chronic hepatitis B (CHB) and metabolic dysfunction-associated steatohepatitis (MASH). This page aggregates official press releases and verified news about the company’s clinical developments, research breakthroughs, and strategic partnerships.
Investors and industry professionals will find timely updates on ALGS’ pipeline candidates including oral capsid assembly modulators targeting viral suppression in CHB and THR-β agonists addressing liver fat reduction in MASH. The curated news collection provides essential context for understanding clinical trial progress, regulatory milestones, and scientific advancements.
Key content categories include updates on: Phase 1-3 clinical trials, collaborative research initiatives, regulatory communications, and therapeutic mechanism insights. All information is sourced from official company disclosures and reputable industry publications.
Bookmark this page for structured access to ALGS’ evolving scientific narrative. Check regularly for developments in oligonucleotide-based therapies and small molecule candidates progressing through clinical evaluation.
Aligos Therapeutics (NASDAQ: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral disease therapies, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management team will deliver a presentation on Thursday, June 5, 2025, at 2:00 PM ET. Interested parties can access the live webcast through the Presentation & Events section of Aligos' investor relations webpage. A replay will remain available for at least 30 days following the presentation.
Aligos Therapeutics (Nasdaq: ALGS) has appointed Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately. Kavanaugh brings over 25 years of experience in the biotechnology and pharmaceutical industries. She most recently served as Vice President, Corporate Law & Privacy Officer at Codexis. Her previous roles include being an independent legal consultant for companies like Genentech and Elan Pharmaceuticals, and serving as Practice Group Leader for BioOncology Development Law at Genentech.
The appointment was announced by Lesley Ann Calhoun, Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Aligos, who emphasized Kavanaugh's extensive knowledge and broad expertise in legal matters. Kavanaugh holds a BA from UC Berkeley and a JD from Santa Clara University Law School.
Aligos Therapeutics (NASDAQ: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced an inducement grant for a newly hired employee. The grant, approved by the Company's Compensation Committee, consists of non-qualified stock options to purchase 26,000 shares of company stock.
The options were granted on May 13, 2025, with an exercise price equal to the closing price on the grant date. The shares will vest over 4 years, with 25% vesting after the first year and the remainder vesting monthly thereafter, contingent on continued employment. This grant was made under Aligos' 2024 Inducement Plan, specifically designed for equity awards to new hires, in compliance with Nasdaq Listing Rule 5635(c)(4).
Aligos Therapeutics (NASDAQ: ALGS) presented positive data from eight presentations at EASL Congress 2025, highlighting significant progress in their liver disease pipeline. The 96-week data for ALG-000184 showed remarkable results in chronic hepatitis B treatment, with 100% of subjects achieving HBV DNA viral suppression. In HBeAg+ subjects, 9/9 achieved HBV DNA suppression by Week 96, while all HBeAg- subjects (11/11) showed rapid decline and sustained suppression by Week 24.
Additionally, their THR-β agonist ALG-055009 demonstrated strong potential in MASH treatment, showing up to 46.2% placebo-adjusted median relative reductions in liver fat at Week 12. Notably, 11/14 subjects on stable GLP-1 agonists treated with ALG-055009 showed liver fat decreases, while maintaining a favorable tolerability profile with gastrointestinal-related adverse events similar to placebo.
Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biotech company specializing in liver and viral disease treatments, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 6, 2025. The results will be released before U.S. financial markets open.
The company, based in South San Francisco, focuses on developing best-in-class therapies aimed at improving patient outcomes in liver and viral diseases. This upcoming financial report will provide insights into the company's performance during Q1 2025.
Aligos Therapeutics (Nasdaq: ALGS) announced that eight abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2025, scheduled for May 7-10, 2025 in Amsterdam. The presentations focus on two key drug candidates:
1. ALG-000184: A potential first/best-in-class small molecule CAM-E for chronic hepatitis B virus infection, with three abstracts highlighting its profound HBV DNA suppression in 96-week studies and resistance barrier analysis.
2. ALG-055009: A potential best-in-class thyroid hormone receptor beta agonist for Metabolic Dysfunction-Associated Steatohepatitis (MASH), with four abstracts demonstrating significant reductions in atherogenic lipids and liver fat, including studies in combination with GLP-1 receptor agonists.
Aligos Therapeutics (ALGS) announced positive data from three presentations at APASL 2025, highlighting significant progress in their liver disease treatments. ALG-000184 demonstrated strong antiviral activity in chronic hepatitis B patients, with 100% of HBeAg+ subjects (9/9) and 91% of HBeAg- subjects achieving sustained HBV DNA suppression, with no viral resistance observed up to 96 weeks.
The company's ALG-055009 showed promising results in MASH patients, with doses of 0.5-0.9mg achieving placebo-adjusted median relative reductions in liver fat up to 46.2%. Up to 70% of subjects achieved ≥30% reduction in liver fat. Notably, 11/14 subjects on stable GLP-1 agonists treated with ALG-055009 showed liver fat decreases, while all 4 placebo subjects on GLP-1 agonists experienced increases.
Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The company's Compensation Committee approved a non-qualified stock option to purchase 4,000 shares for a newly hired employee on March 11, 2025.
The grant, issued through Aligos' 2024 Inducement Plan, serves as an employment inducement and has an exercise price matching the closing price of Aligos' common stock on the grant date. The shares will vest over four years, with 25% vesting after the first year and the remaining portion vesting in equal monthly installments, contingent on continued employment.
FAQ
What is the current stock price of Aligos Therapeutics (ALGS)?
What is the market cap of Aligos Therapeutics (ALGS)?
